Tvardi Therapeutics, Inc.
TVRD
$3.98
$0.020.51%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.63M | 8.74M | 8.84M | 7.39M | 4.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.45M | 26.75M | 29.96M | 29.70M | 28.01M |
| Operating Income | -29.45M | -26.75M | -29.96M | -29.70M | -28.01M |
| Income Before Tax | -15.44M | -18.21M | -23.65M | -23.63M | -34.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.44 | -18.21 | -23.65 | -23.63 | -34.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.44M | -18.21M | -23.65M | -23.63M | -34.77M |
| EBIT | -29.45M | -26.75M | -29.96M | -29.70M | -28.01M |
| EBITDA | -29.35M | -26.65M | -29.87M | -29.61M | -27.92M |
| EPS Basic | -1.58 | -4.58 | -8.74 | -10.29 | -13.50 |
| Normalized Basic EPS | -0.99 | -2.86 | -5.46 | -6.43 | -8.44 |
| EPS Diluted | -3.10 | -6.09 | -10.25 | -11.80 | -13.51 |
| Normalized Diluted EPS | -1.00 | -2.87 | -5.47 | -6.44 | -8.44 |
| Average Basic Shares Outstanding | 36.39M | 29.58M | 22.77M | 15.97M | 10.30M |
| Average Diluted Shares Outstanding | 36.59M | 29.79M | 22.98M | 16.18M | 10.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |